Acinetobacter baumannii, bacteremia; mortality; risk factors Background/Purpose: Identification of risks of mortality for carbapenem-resistant Acinetobacter baumannii (CRAB), with early implementation of an appropriate therapy, is crucial for the patients' outcome. The aim of this study was to survey mortality risk factors in 182 patients with CRAB bacteremia in a medical center in Taiwan 
Introduction
Acinetobacter species belong to a group of Gram-negative coccobacilli commonly found both in the environment (such as in water, food, and soil) and in the humans (such as in skin, wounds, and respiratory and gastrointestinal tracts). 1 The Acinetobacter calcoaceticuseAcinetobacter baumannii complex (AB complex) consists of four genotypically distinct, but phenotypically very similar, bacterial species: A. calcoaceticus (an environmental species), A. baumannii, Acinetobacter pittii, and Acinetobacter nosocomialis. In the past decade, AB complex comprising A. baumannii, A. pittii, and A. nosocomialis has become a common pathogenic cause of health care-associated infections. Associated infections include pneumonia, urinary tract infections, bacteremia, soft tissue infections, meningitis, and empyema. 2 Carbapenem-resistant strains of AB complex have been reported worldwide. These antibiotic resistant strains accounted for 14.1% and 39.4% of all health careassociated infections in Europe and Latin America, respectively, with a worldwide prevalence of 30%. 7, 8 From 2000 to 2005, the prevalence of imipenem-resistant AB complex in Taiwan increased from 22% to 25%. 9 Data from the Taiwan Surveillance of Antimicrobial Resistance show that the prevalence of multidrug-and carbapenemresistant A. baumannii (CRAB) complex infections has reached 60e66.8% in recent years. 10 The high incidence rate of CRAB complex infections, especially CRAB, in Taiwan is a threat to numerous patients in the health care system and presents a difficult challenge for hospital infection control. Given limited drug choices and a high infection mortality rate, treatment of CRAB is difficult. 4 Patients with CRAB infections have a higher mortality rate than those infected with AB strains susceptible to carbapenem.
11e14
The risk factors of mortality of CRAB complex bacteremia have been reported in different parts of the world in recent years.
15e20 However, A. baumannii cannot be differentiated from AB complex using phenotypic methods. 21, 22 Currently, only a few articles have reported the information concerning the comorbidities associated with mortality risk factors in CRAB bacteremia. 23e25 The aim of this study was to survey mortality risk factors associated with CRAB bacteremia.
Methods
Bacterial isolates, identification, and clonality determination 26 were collected in Mackay Memorial Hospital, a 2200-bed, tertiary teaching hospital in Taiwan. For patients with ! 2 positive blood cultures, only the first isolate was included. They were phenotypically identified as AB complex by the Vitek 2 system (bioMérieux Vitek Systems Inc., Hazelwood, MO, USA) in a microbiology laboratory. Susceptibility tests were also performed using the Vitek 2 system. Isolates were kept frozen at À70 C in trypticase soy broth (BD, Sparks, MD, USA) containing 20% glycerol (v/v) until further testing. Genotypic identification of A. baumannii was performed by identifying the presence of the bla OXA -51-like carbapenemase gene that is specific to the A. baumannii species. 27 Identification of other species in AB complex was performed by sequence analysis of rpoB and flanking spaces, according to the protocol by La Scola et al. 28 Finally, isolates were digested with ApaI (New England Biolabs, Beverly, MA, USA) and evaluated with pulsed-field gel electrophoresis to determine clonality. 29 
Study population and data collection
We retrospectively reviewed medical charts of patients infected with CRAB complex and having symptoms and signs of infection. Patients aged > 1 year were included if they had bacteremia due to CRAB complex, regardless of primary infection sites. Patients with CRAB bacteremia were selected for further clinical analysis after genotypic identification from CRAB complex. This retrospective study was approved by the Mackay Memorial Institutional Review Board (protocol numbers 13MMHIS122 and 13MMHIS291).
Medical records were reviewed and the data on the following parameters were collected: patient characteristics, source of bacteremia, comorbidities, previous antimicrobial use, invasive procedure use (Table 1) , whether or not the patient was in the intensive care unit (ICU) at the time of onset of bacteremia, and the patient's Acute Physiology and Chronic Health Evaluation II (APACHE II) score. Documentation of previous antibiotic use included antibiotics that were given to the patient in the14-day period prior to the onset of bacteremia. Central line-associated infection was defined according to the United States Centers for Disease Control and Prevention guidelines. 30 Liver cirrhosis was diagnosed by gastroenterologists based on laboratory and radiological evidence. Chronic kidney disease was defined as an estimated glomerular filtration rate of < 60 mL/minute/1.73 m 2 . An appropriate antimicrobial therapy was defined as the administration of at least one antimicrobial agent, to which a pathogen was sensitive in vitro, within 48 hours of bacteremia, with an approved route and dosage appropriate for end organ function. Otherwise, a therapy that did not meet these criteria was considered inappropriate. A therapy was considered inappropriate if only an aminoglycoside was used. 31 Attributable mortality indicated that a patient died during the admission period of the CRAB bacteremia episode. 
Statistical analysis
The hazard ratios (HRs) of uni-and multivariate analyses were performed using a Cox proportional hazards ratio model (Cox PH regression). For all analyses, a two-tailed p < 0.05 was considered significant. All biological variables with p < 0.05 in the univariate analysis were included in the Cox PH regression for multivariate analysis. SPSS version 21.0 (SPSS Inc., Chicago, IL, USA) was used for performing the statistical analysis.
Results
A total of 195 AB complex blood isolates were collected during the study period. There were 182 CRAB, 11 carbapenem-resistant A. nosocomialis, and two carbapenem-resistant A. pittii isolates. The pulsed-field gel electrophoresis patterns of 182 CRAB isolates were identified as belonging to 38 different pulsotypes, as presented in Fig. 1 In multivariate analysis, the independent risk factors for mortality included stay in ICU [HR: 2.27; 95% confidence interval (CI): 1.21e4.26; p Z 0.011), APACHE II scores of >20 (HR: 2.19; CI: 1.42e3.36; p < 0.001), respiratory tract as the origin of bacteremia (HR: 3.40; CI: 2.04e5.67; p < 0.001), and use of ceftriaxone prior to the onset of CRAB bacteremia (HR: 2.51; CI: 1.23e5.09; p Z 0.011).
The sensitivity of CRAB to meropenem was 0% (0/182), to colistin was 100% (Fig. 2) , and to tigecycline was 40.11%. The MICs of colistin and tigecycline for CRAB are listed in Fig. 3 . Of the isolates, 3.85% and 7.14% had tigecycline MIC < 0.5 mg/L and MIC < 1.0 mg/L, respectively, while 61.54% and 76.92% had colistin MIC < 0.5 mg/L and MIC < 1.0 mg/ L, respectively. The percentage of appropriate antimicrobial therapy among the182 CRAB bacteremia patients was 18.87% (20/106) in the mortality group versus 88.16% (67/76) among survivors (p < 0.001). The appropriate therapy included a colistin-based therapy (85 patients; 20 in the mortality group and 65 in the survival group), either a monotherapy or a combination therapy. Of the patients, Figure 1 . Demonstration of 38 pulsotypes from 182 Acinetobacter baumannii blood isolates. PFGE Z pulsed-field gel electrophoresis.
76.47% (65/85) under an appropriate antimicrobial therapy (colistin-based therapy) survived. Two patients received an appropriate therapy with tigecycline and both of them survived after management.
Discussion
A. baumannii is distinct from A. nosocomialis and A. pittii in that it possesses greater antimicrobial resistance and results in more severe patient outcomes. However, in routine clinical practice, all these bacteria present similar phenotypic reactions, cannot be readily identified, and are instead reported as AB complex.
3e6 This generalization becomes a challenge in research on infections, since the AB complex infection is caused by a mixture of different Acinetobacter species. Therefore, it is reasonable to separate A. baumannii from AB complex in research studies, and investigate its distinct risk factors and survival analysis.
With its intrinsic resistance to many antibiotics and rapid acquirement of resistance mechanisms, A. baumannii adapts to the hospital environment quickly and can cause outbreaks that are difficult to control. 31 CRAB infections are independently associated with increased hospital mortality, as well as prolonged ICU and hospital stays. 12, 13 In an investigation of risk factors for the isolation of multidrugresistant A. baumannii, Falagas et al 32 suggested that a separate outbreak investigation should be performed in each hospital setting, and innovative control strategies should be developed to limit the spread of pathogens. Since a central line-associated source (41/182, 22.53%) was related to CRAB bacteremia, we suggest that a care bundle intervention be utilized to reduce central line-associated bacteremia in high-risk units. The central line bundle would include the several key components according to the United States Centers for Disease Control and Prevention guidelines. 30 It is hoped that with the implementation of a central line bundle in our institution, we can decrease incidences of central line-associated bacteremia through infection control measures. Cleaning of the environment is also needed for decreasing the incidence of CRAB overgrowth.
Given that ceftriaxone is ineffective against CRAB, its previous use was found to be associated with increased mortality in CRAB bacteremia in this clinical analysis. Our CRAB isolates from blood showed 100% sensitivity to colistin and 40.11% sensitivity to tigecycline. In general, colistin is the preferred drug of choice for treatment of CRAB, except in the case of severe renal insufficiency. Lee et al 33 found that an appropriate antimicrobial therapy can significantly reduce the 14-day mortality of patients with A. baumannii bacteremia. In this study, the rate of appropriate antimicrobial therapies for CRAB in the mortality group and survivors were 18.87% and 88.16% (p < 0.001), respectively. These results clearly indicate that an appropriate antimicrobial therapy can influence the survival rate in bacteremia caused by CRAB infections.
The attributable mortality rate of the 182 patients with CRAB bacteremia was 58.24% (106/182). Liver cirrhosis was a risk factor for attributable mortality among CRAB bacteremia patients under univariate analysis. High mortality (72.73%, 8/11) within 14 days after onset of bacteremia was found in 11 liver cirrhosis patients with CRAB bacteremia. There are very few previous large-series studies regarding A. baumannii infections associated with liver cirrhosis. 34 Four of the 11 liver cirrhosis patients died within 24 hours after blood cultures were obtained. Two of the three surviving liver cirrhosis patients received colistin within 24 hours, while one of the three patients received colistin within 48e72 hours after blood culture. Controversy surrounds the benefits of combination treatment or monotherapy against multidrug-resistant A. baumannii infections in clinical practice. According to a systematic review of the literature, combination treatment may be preferred for severely ill patients. 35 Combination treatment with colistin is preferred in severely ill patients, for example, ICU patients with CRAB bacteremia.
The limitation of this study is that this study was conducted in a single medical center, and the results may not be applied to other hospital. We use attributable mortality as the endpoint of our study, which is a relatively subjective endpoint. However, there is also an inherent bias for using overall mortality in the study of A. baumannii infection, because the hosts are frequently immunocompromised and had multiple underlying diseases, which may contribute to the mortality.
In conclusion, the independent risk factors for mortality in patients with CRAB bacteremia included stay in ICU, APACHE II scores of > 20, respiratory tract as the origin of bacteremia, and use of ceftriaxone prior to the onset of CRAB bacteremia. Rapid identification of patients at risk of mortality and early implementation of an appropriate antimicrobial therapy are crucial for patients with CRAB bacteremia, especially those with liver cirrhosis.
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